Disruptive surface chemistry for biosensors,
enabling the development of innovative rapid diagnostic assays.
Current biosensing solutions are limited in sensivity and specificity. This lack of reliability is mainly due to the surface chemistry used at the interface between the sensor and the biological sample.
Built on 10 years of academic research, our patented surface chemistry removes background noise by protecting the surface against non-specific interactions, and improves sensitivity by optimizing the ligand density, repartition and orientation towards the target biomolecules.
Our versatile technology can be applied on gold nanoparticles for lateral flow assay development, as well as on gold biochips for efficient in vitro analysis.
Products & Services
A paradigm shift in bio-functionalization
Kimialys delivers the highest-quality surface chemistry for gold nanoparticles and biochips.
Our products and services are dedicated to all biosensor users involved in healthcare: lateral flow developers, biotechnology companies, pharmaceutical companies, CROs and academic research teams.
Functionalized gold nanoparticles
Bio-conjugaison kits for gold nanoparticles
Functionalized gold biochips
Bio-conjugaison kits for gold biochips
Custom surface chemistry for your applications (lateral flow assay, SPR)
Biomolecular interaction analysis for your specific measurements
Removal of background noise thanks to optimal protection of the surface
How we fit your needs
Lateral Flow Assay
Whether you are looking to develop a new challenging assay, improve the performance of your existing products or reduce the cost of production, Kimialys is a one-stop shop for all lateral flow developers.
Specifically developed for gold nanoparticles, our surface chemistry is a game changer for the lateral flow industry.
Surface Plasmon Resonance
SPR applications for molecular interaction analysis are still limited today due to non-specific interactions occurring at the surface of gold biochips.
Kimialys removes background noise, enabling the user to work at the limit of detection of the instrument itself.
SPR at its full potential.
Kimialys is the result of 10 years of academic research on surface chemistry for biosensing, identified as the Achilles Heel of biosensors. Pioneered by the Laboratory of Biology and Applied Pharmacology (ENS Paris-Saclay/CNRS), our technology was further improved during a maturation program between 2017 and 2019 at the SATT Paris-Saclay technology transfer office.
Kimialys was born in 2020 to democratize our disruptive technology within healthcare applications.
We built our company to support the development of cutting-edge biosensing products that could not exist but for our work, and that will have a major impact for people's health.
We focus our current efforts on Diagnostic Tests, helping our customers bring reliable, rapid, cost-effective diagnostic tests.
Dr. Claude Nogues has been working on the development of Kimialys' patented technology for the past 10 years, as a CNRS researcher at the ENS Paris-Saclay. She is expert in physical-chemistry, biophysics, surface and colloid chemistry.
Cyril Gilbert spent the past 3 years as a tech investor at Jolt Capital, and holds a double degree in engineering and management (Institut d'Optique & HEC Paris). He joined Claude to found Kimialys and speed up the development of high-performance diagnostic solutions.